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Synopsis 
Multiple Sclerosis is a multifactorial disease with heterogeneous pathogenetic mechanisms, 
which deserve to be studied in order to evaluate new possible targets for treatments and improve 
patient management. MR Spectroscopy and Positron Emission Tomography allow assessing in-vivo 
the molecular and metabolic mechanisms underlying the pathogenesis of MS. Thus, the present 
review will focus on the relationship between these imaging techniques and the biological and 
chemical pathways leading to MS pathology and its clinical features. Future directions of research 
will be presented. 
  
Key points 
1. Molecular and metabolic imaging techniques assess dynamically and in-vivo the 
pathogenetic mechanisms that lead to MS pathology and reflect the heterogeneity of pathological 
abnormalities occurring in MS. 
2. 1H-MR Spectroscopy estimates brain levels of several metabolites, which reflect important 
biological processes, such as mitochondrial function and/or neuronal integrity (N-Acetyl-Asparate), 
and glial cell activation and proliferation (Myo-inositol). The concentrations of two 
neurotransmitters, Gamma-Amino-Butyric Acid, and Glutamate, can also be quantified. 
3. 23Na MRI estimates the total concentration of sodium within regions-of-interest in the 
brain. Increased total sodium concentration is thought to reflect axonal impaired energy metabolism 
and neurodegeneration. Advanced techniques are needed to distinguish between the intracellular 
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and extracellular sodium concentration. 
4. Positron Emission Tomography permits the characterisation of the biological processes 
occurring at the cellular and molecular levels. The following radioligands are often used: 18F- 
fluoro-2’-deoxyglucose to investigate inflammation, translocator protein tracers to study microglia 
activation, amyloid tracers to study demyelination, and 11C-Flumazenil to investigate neuronal 
damage.   
5. Although technically challenging and expensive, the translation of these techniques to 
clinical trials and the clinical setting may allow stratification of patients for treatments.   
 
 
Introduction 
Tags: Multiple Sclerosis; relapsing–remitting; progressive; grey matter; white matter; pathology; 
molecular and metabolic imaging. 
 
Recent advances in conventional Magnetic Resonance Imaging (MRI) have remarkably 
improved the diagnosis of multiple sclerosis (MS), which can now be achieved earlier and with 
greater precision. T2 lesions and brain atrophy estimated with MRI are currently used in clinical 
trials as outcome measures. However, conventional neuroimaging techniques lack of specificity 
with regard to different pathophysiological substrates of MS, and are not able to explain the 
heterogeneous and long-term clinical evolution of this disease.1–4 
MS usually starts with a relapsing–remitting course (RRMS), characterized by the subacute 
occurrence of neurological symptoms (namely relapses) that may be followed-up by a clinical 
improvement. In view of this, the presence of focal areas of inflammatory demyelination in the 
white matter (WM), known as plaques and responsible for relapses, has been considered the main 
pathological feature of MS. After 15–25 years from disease onset, the clinical course of MS 
typically shifts into a progressive course, which is termed secondary progressive MS (SPMS). 
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However, a small group of patients (10–15%) develop a progressive course of the disease since 
onset, and this type of MS is called primary progressive MS (PPMS).  
The main pathological mechanism underling the progressive course of MS is thought to be 
neurodegeneration. The occurrence of neurodegenerative features are considered to be both a 
consequence of the inflammatory activity,1,5,6 and a primary neurodegenerative component 7. 
Neurodegeneration occurs diffusely in the brain and spinal cord of MS patients, and is reflected by 
changes in structural imaging parameters that can be measured within and outside lesions, namely 
in the normal appearing WM (NAWM) and grey matter (GM).8  
The pathogenesis of MS is not fully understood, and it is thought that there is a series of 
pathobiological events, starting with focal lymphocytic infiltration and microglia activation, and 
ending with demyelination and neuroaxonal degeneration (Figure 1). In particular, a primary 
stimulus (either endogenous or exogenous) may be responsible for an inflammatory, demyelinating 
response, which induces a compensatory response within neurons. This response, which includes 
the redistribution of sodium channels along the demyelinated axolemma and increased 
mitochondrial metabolism, might have a transient functional benefit, but may be deleterious in the 
long-term. Specifically, oxidative stress, mitochondrial injury and ion channel dysfunction have 
been suggested as possible “maladaptive” changes, leading to neuroaxonal damage (Figure 1).1,9 
Molecular and metabolic imaging have the unique ability to reflect in-vivo some of the molecular 
and metabolic pathways involved in the development and progression of neurodegeneration in 
MS.2,10 
The present review will describe and discuss clinical studies that used molecular and 
metabolic imaging techniques to investigate the role of specific molecular, (sub)cellular, and 
metabolic processes in causing neurodegeneration in MS. The most successful techniques are 1H-
MR Spectroscopy (MRS), Sodium imaging, and Positron Emission Tomography (PET); these 
techniques have been often used to provide insights into the pathogenesis of MS in-vivo and explain 
the clinical heterogeneity of MS patients. Translation of these techniques to clinical trials and the 
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clinical setting may facilitate the development of effective treatments in MS and help to stratify 
patients for treatments.  
 
MR spectroscopy 
Tags: Metabolic imaging; spectroscopy; proton; sodium; choline; NAA; GABA; Glutamate; Myo-
Inositol. 
 
MR Spectroscopy (MRS) is used to study metabolites in the brain, as long as they are 
available in relatively high concentrations and present one or more MR visible nuclei (for more 
details on MRS see the book by Gülin Oz Editor).11 The most common nucleus that is used is 1H 
(proton). In MS, 1H-MRS is used to provide in-vivo quantification of brain levels of several 
metabolites. Each metabolite appears at a specific ppm (part per million), and each one reflects 
specific cellular and biochemical processes; therefore, their concentrations may change in 
association with pathological abnormalities. The most commonly estimated metabolites are: total N-
acetyl-asparate (NAA) (which includes NAA and N-acetylaspartylglutamate), glutamate (Glu), 
gamma-amino-butyric acid (GABA), creatinine (Cr), choline-containing compounds (Cho) and 
myo-inositol (Table 1) (Figure 2). These metabolites can be estimated within lesions or in the 
normal-appearing brain.  
We will now review the most recent clinical studies that detected abnormal levels of 
metabolites in MS patients when compared to healthy controls, by going through the metabolites 
from the right of the spectrum to the left, and discuss the findings of abnormal levels of metabolites 
in the brain (lesions, NAWM and GM) and spinal cord. 
  
N-Acetyl-Aspartate 
NAA is synthesized by neural mitochondria and is almost exclusively located within neural 
cells in the mature brain.2,10,12–14 Although its biochemical functions are not completely understood, 
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NAA might reflect neuronal mitochondrial metabolism and/or neuronal integrity (Figure 1) 10. 
Since metabolic (mitochondrial) dysfunction is considered to play a role in the neurodegeneration, 
the in-vivo estimation of NAA levels may provide insights into the mechanisms of damage and 
recovery in MS.  
NAA levels can either be calculated as absolute concentrations or as values normalised to 
intravoxel Cr (NAA/Cr); advantages and disadvantages of both methods have been previously 
discussed.15 In their meta-analytic review including 30 studies evaluating NAA in MS, Caramanos 
and colleagues found that the directions of change in mean NAA values and mean NAA/Cr ratios 
were concordant in most studies, suggesting the use of these measures as a practical compromise to 
the acquisition of a surrogate measure of “cerebral tissue integrity”.12,16 
In acute lesions there is a reduction of NAA levels when compared with the surrounding 
NAWM,17 and with the WM of healthy controls,18 suggesting neuronal loss and/or metabolic 
dysfunction; the reduction of NAA may be, at least in part, due to the local oedema, which is 
associated with acute inflammation. Similarly, in chronic WM lesions (hypointense on T1-weighted 
images), there is an overall mean decrease in NAA levels of about 20%.12 
When the temporal behaviour of NAA is examined over time, MRS studies in the brain and 
spinal cord have found that reduced NAA levels in acute lesion partially recovers over time, 
although it does not return to normal.17,19,20 Since at the same time, progressive atrophy occurred, it 
is possible that increased NAA levels indicate the enhanced mitochondrial activity that is necessary 
to restore and maintain axonal conduction after acute inflammatory demyelination. The resolution 
of oedema or a change in the relative partial volume of neuronal processes may also play a role in 
increasing the NAA levels after an acute damage.  
 In the MS NAWM, there is an overall mean decrease of NAA of about 7% when compared 
to healthy WM;12 greater reductions in NAA were found in the progressive forms of MS. Patients 
with clinically isolated syndrome (CIS) showed reduced,21,22 or normal NAA levels in the NAWM 
when compared to controls.23,24 In a previous study in CIS patients, WM NAA/Cr was significantly 
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lower in patients who developed new T2 lesions on MRI and/or relapses during the follow-up than 
in stable patients,25 suggesting that neuroaxonal damage may be already well established in patients 
at such an early disease stage and thus indicates a more aggressive disease course. Similarly, a 
relationship between lower NAA levels in several WM regions and higher clinical disability, as 
assessed by the MSFC, has been described in patients with RRMS.26 Interestingly, 18 recently 
diagnosed, mildly disabled, RRMS patients, all on immunomodulatory medication, showed a 6% 
lower WM NAA than controls at study entry, but an increase in NAA over three years, at a rate of 
0.1mM/year;27 this increase of NAA levels may indicate a neuronal dysfunction which may 
improve with treatment. 
 In the GM, NAA levels were found to be consistently reduced in the thalamus and 
inconsistently reduced in the cortex of MS patients when compared to healthy controls,12,28–30 
suggesting neuroaxonal damage and loss. Two different studies conducted in PPMS, RRMS and 
SPMS patients showed that GM NAA alterations involve the thalamus and the lymbic system,26,29 
although they might be more diffuse and involve also the prefrontal and motor areas. Lower NAA 
in the bilateral caudate nucleus was found to correlate with higher clinical disability.26 
Lower NAA levels were found in the spinal cord of 21 patients with early PPMS when 
compared to healthy controls, and were associated with higher motor disability, as measured by the 
EDSS (Expanded Disability Scale Score),31 suggesting that neurodegeneration may occur in the 
spinal cord in the early phase of progressive MS, even in the absence of significant spinal cord 
atrophy. 
Overall, all these studies have supported the use of NAA as marker of axonal loss and/or 
metabolic dysfunction, and a few clinical trials have used it as a secondary outcome measure to 
assess the efficacy of experimental treatments in MS.32,33 Recommendations and advice on how to 
introduce the measurement of NAA levels in clinical trials have been previously provided by the 
MAGNIMS group.15 
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Glutamate and Glutamine 
In 1H-MRS, Glu is generally quantified together with Glutamine (Gln), which is both its 
precursor and catabolite, although Glu makes up the majority of the Glx signal (Glu + Gln = Glx). 
Glu is an important excitatory neurotransmitter, and its in-vivo quantification can be obtained by 
using specific techniques, allowing unobstructed Glu signal detection.  
Increased extracellular Glu concentrations in MS can be determined by enhanced production 
by inflammatory cells (macrophages and microglial cells), reduced uptake in oligodendrocytes and 
in astrocytes, and increased receptor expression. Increased Glu levels may contribute to 
neuroaxonal degeneration, through the mechanism of “excitotoxicity” (Figure 1).10,34 An elevation 
of Glu levels has been found in active WM lesions.35 
Glu and Gln levels have been found to be increased in the NAWM in different disease 
subtypes (PPMS, RRMS, and SPMS) when compared with healthy controls.34,36 Interestingly, over 
the course of MS, there is evidence of a progressive reduction in their concentrations within the 
NAWM, compared to other markers, such as NAA, which, on the opposite, remains substantially 
stable. Therefore, Glu might increase at an early stage (with suggested toxic effects), and then 
progressively decline, reflecting progressive neurodegeneration.36 A longitudinal study on 343 MS 
patients (mainly RRMS), showed that higher Glu concentration in the NAWM was associated with 
higher rate of NAA decline after 2 years, higher rate of brain volume loss after 3 years, and greater 
disability progression after 4 years, measured with the MS functional composite score.34 Therefore, 
the authors suggested that the Glu/NAA ratio might be a more biologically relevant predictor than 
either metabolite alone, since when using this ratio the Glu concentrations are adjusted for the 
amount of the neuronal dysfunction (as measured by NAA).34 
Glu and Glx concentration have been found to be reduced in the parietal and cingulate GM 
regions in patients with RRMS when compared to controls.26,37 In addition, impairment of the 
visuospatial memory was significantly associated with lower hippocampal, cingulate and thalamic 
Glu levels, independently from other measures of GM damage.37 Similarly, a previous study found 
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reduced Glx in the cortical GM in the brains of patients with early PPMS when compared to 
controls.38 Since Glu is more abundant inside cells and in the synaptic terminals than in the 
extracellular space, a possible interpretation of its reduced concentration is a reduction in the 
number of synapses and neuroaxonal degeneration, which have been described in post-mortem 
studies of MS brains.39 
Reduced Glx levels were also found in the spinal cord of 21 patients with early PPMS when 
compared to 24 controls,31 suggesting that reduced glutamatergic metabolism occur in the early 
phase of the disease. As mentioned above, it is more challenging to perform MRS and, in particular, 
to estimate the levels of Glx, in the spinal cord than in the brain.  
Blocking Glu receptors seems a promising therapeutical approach to slow down disease 
progression and, for instance, memantine has been utilized in different clinical trials to improve 
cognitive function in MS.40 In future, the efficacy of medications targeting the glutamatergic 
metabolism could be monitored by using MRS.  
 
Gamma-Aminobutyric Acid 
GABA is the major inhibitory neurotransmitter in the brain, and can be evaluated with 1H-
MRS by using spectral editing method that allows its discrimination from more abundant 
metabolites. 
Measurements of GABA in brain lesions and NAWM have not been reported so far.  
With regard of the GM, GABA levels have been found to be reduced in the hippocampus and 
sensorimotor cortex in 30 SPMS patients when compared to 17 healthy controls.41 The reduction of 
GABA in the sensorimotor cortex was associated with a more impaired motor function of the 
contralateral limbs.41 Previous post-mortem studies have detected a loss of GABAergic inhibitory 
interneurons in the temporal cortex of MS patients with seizures,42 and a decrease in presynaptic 
and postsynaptic components of GABAergic neurotransmission and in the density of inhibitory 
interneuron processes in MS cortex.43 Therefore, GABA has been suggested to be a marker of 
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neurodegeneration. Additionally, it is thought that reduced cerebral levels of GABA reflect 
impaired compensatory mechanisms occurring in the damaged areas of the brain in progressive 
MS.2,41 
Agonists of the GABA receptor may be used to manage symptoms associated with MS; for 
example, baclofen is commonly used to ameliorate spasticity and topiramate is used by some 
patients with established MS who also have epilepsy or migraines. It has been demonstrated that 
increasing GABAergic activity may be beneficial for animals with EAE (Experimental 
Autoimmune Encephalomyelitis) (animal model of MS) and that this effect occurred, at least in 
part, through a direct effect of the GABAergic agents on the immune system,44 suggesting that 
further studies are needed to establish whether GABAergic agents may have an effect on underlying 
MS disease activity and whether MRS can be used to monitor it. 
 
Creatine 
Cr reflects energy metabolism. A meta-analysis has reported no significant overall change in 
the Cr in MS lesions and GM when compared to WM and GM of healthy controls, and a medium-
effect-sized overall increase in the Cr of NAWM relative to WM. In a recent study, Cr has been 
found to be increased within the corticospinal tract, which is characterized by a high metabolic rate, 
of RRMS and PPMS patients when compared to controls.45 Lower Cr levels within the corticospinal 
tract were associated with higher motor disability in 13 PPMS and 14 RRMS patients, suggesting 
that an impaired energy metabolism can be responsible for clinical features of MS.18,45 
 
Choline-containing compounds 
Cho is a marker of cell membrane, and its increase reflects elevated cellular turnover. It is 
often reported to be raised in the NAWM of MS patients when compared to controls.27 Narayana 
and colleagues described the elevation of Cho before the appearance of a Gadolinium-enhancing 
lesion, suggesting that Cho might be a marker of inflammation preceding demonstrable blood-brain 
 12 
barrier breakdown.17 
When Cho is measured along the whole cortico-spinal tract, it was higher in 13 RRMS when 
compared to 16 healthy controls, but similar between RRMS and PPMS patients. In addition, in the 
PPMS group, lower Cho levels were associated with worse walking abilities and greater disability, 
as measured by the EDSS, suggesting that abnormal membrane turnover from demyelination and 
remyelination, which is reflected by lower Cho levels, might be responsible for disability accrual.45 
However, these correlations were not confirmed by the study of Kirov and colleagues carried out in 
18 RRMS patients with short disease duration and minimal disease activity; additionally, this work 
did not detect significant changes in Cho levels in the GM between patients and controls, 
suggesting that the injury may be focal, subtle or hetereogeneous between cortex and deep GM.27 
Similarly, Donadieu and colleagues did not find any difference in GM Cho levels between 19 
RRMS patients and 19 healthy controls, possibly because of their voxelwise between-group 
analysis, which might have made it difficult to detect the random distribution of Cho.26 
  
Myo-inositol 
Myo-inositol is a glial cell marker, and its increase reflects glial cell (or astrocytic) activation 
and proliferation (Figure 1).10,35,46 
Different disease subtypes (e.g. PPMS and RRMS) show increased myo-inositol levels in the 
acute and chronic WM lesions of the brain and the spinal cord when compared to healthy 
controls.18,26,31,35,47 In a study carried out in 14 RRMS patients, higher myo-inositol levels within 
acute lesions of the spinal cord were associated with greater disability, as measured by the EDSS.18 
Myo-inositol levels were found to be higher in the NAWM of 19 RRMS when compared to 
19 healthy control, especially in the periventricular regions within bilateral temporal and frontal 
lobes, in the left thalamus and superior temporal gyrus.26 A significantly higher myo-inositol 
concentration was found in the corticospinal tract of 13 RRMS patients when compared to 16 
healthy controls, and higher myo-inositol levels were associated with greater walking difficulties. 
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However, in the same study, no difference was found between PPMS and healthy controls, 
suggesting a more widespread glial activation in the corticospinal tract of patients with RRMS.45 A 
study carried out in patients with clinically isolated syndrome (CIS) has reported elevated myo-
inositol levels in the NAWM when compared to control subjects,23 which did not correlate with T2 
lesion load, suggesting that myo-inositol may reflect a process of pathogenic importance, 
independently of WM lesions. However, other studies in CIS patients did not confirm increased 
myo-inositol in NAWM when compared to controls.21,24 
Higher myo-inositol levels were found in the cortical GM and in the thalamus of 19 RRMS 
patients when compared to controls,26 suggesting that astrocytic activation and proliferation involve 
both cortical and deep GM regions in MS. 
Finally, myo-inositol levels have been found to be increased in the lesional upper cervical 
cord of MS patients, when compared to controls and to patients with neuromyelitis optica (NMO),47 
with potentially important diagnostic implications. Reduced myo-inositol values might reflect the 
extent of the damage of astrocytes, which are highly damaged in NMO, but not in MS, where they 
are typically activated and increased in number (i.e. gliosis). 
 
Limitations 
From a technical point of view, there are several limitations of MRS imaging,11 which may 
hamper their use in the clinical setting and in clinical trials.15 These include: 1) long acquisition 
times, more significantly for chemical-shift imaging (CSI) than for single-voxels MRS; 2) lower 
spatial resolution compared to MRI,46 with minimal spatial information provided by single voxel 
MRS acquisition; 3) difficulties in differentiating between the intracellular and the extracellular 
pool of different metabolites and between GM and WM compartments within volumes of interest; 
4) use of different scanners and acquisition protocols which can be responsible for incomplete 
agreement on metabolite concentrations; 5) spectra are influenced by variations in B0 and B1 
magnetic fields, and there are pathology-related changes in the T1 and T2 relaxation times of the 
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spectral metabolites that need to be considered when investigating patients. Furthermore, spinal 
cord MRS presents additional technical limitations, such as the small size of the cord, the 
susceptibility artefacts due to tissue-bone interfaces, and the motion artefacts arising from 
respiratory, arterial and cardiac activities, and systolic-related CSF and spinal cord pulsations. 
 
Sodium imaging 
In the central nervous system (CNS), sodium concentration is maintained at a markedly lower 
concentration (12mM/L) in the larger intracellular compartment (tissue fraction of 80%), when 
compared to the higher concentration (140mM/L) in the smaller extracellular compartment (tissue 
fraction of 20%), as a result of complex energy-dependent mechanisms (e.g. Na/K pump) (Figure 
1).1 Increased concentration of intracellular sodium is caused by impaired mitochondrial 
metabolism and is considered to play a role in the cascade of event that leads to neuronal death. 
Additionally, in acute inflammatory demyelinated lesions, there is extracellular oedema, with 
increased fluid in the interstitial compartments. Increased extracellular sodium in MS may also 
occur because of the expansion of the extracellular space secondary to neuroaxonal loss.  
Previous sodium MRI studies have estimated the total sodium concentration in the brain, 
without distinguishing between its intracellular and extracellular component.48,49 These studies have 
reported higher total sodium concentrations in lesions, NAWM and cortical GM in MS patients 
when compared to controls, with especially high concentrations detected in patients with higher 
clinical disability and progressive MS.49 These findings suggest that raised total sodium 
concentration may reflect neuroaxonal damage, which is responsible for progression and increased 
disability. However, also patients with early RRMS show abnormally high total sodium 
concentrations, although limited to a certain number of brain regions (brainstem, bilateral 
cerebellum, left temporal pole) and the GM.50 
More recently, the use of ultra-high field MRI has allowed the discrimination of intracellular 
and extracellular sodium concentrations. Petracca and colleagues have performed a triple-quantum 
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filtered (TQF) 23Na MRI with a MR pulse sequence and applied a single quantum and TQF imaging 
at 7 T to quantify intracellular sodium concentration and intracellular sodium volume fraction, an 
indirect measure of the extracellular sodium. Both total and intracellular sodium concentrations 
were increased in the NAWM and in the GM of 19 RRMS, compared to 17 controls, whereas 
extracellular sodium concentrations were reduced; furthermore, reduced levels of extracellular 
sodium were associated with disability, as measured by the EDSS.48 These findings suggest that 
sodium accumulation is not only a consequence of demyelination and neuroaxonal loss, but also a 
marker of metabolic dysfunction. Therefore, measuring the intracellular component might provide 
the unique opportunity to identify metabolically dysfunctional brain areas, which might be targeted 
by new drugs restoring their function and, so, preventing irreversible structural alterations. 
 
 
Positron Emission Tomography 
Tags: Molecular imaging; Positron Emission Tomography; radioligand; tracer; FDG; amyloid; 
myelin; acetate; adenosine; choline; Flumazenil; GABA; TSPO. 
 
PET is a quantitative imaging technique, which investigates cellular and molecular processes 
in vivo. It requires the reconstruction of an image of the tissue of interest after the distribution of an 
exogenously administrated positron-emitting molecule, ideally binding a selective target.46,51 
As MS is a complex and multifactorial disease, there are different possible radioligands, 
which can be used in PET imaging with relatively high selectivity. Examples of the targets of the 
PET radioligands used in MS are shown in Figure 1.  
We now discussed the results of the studies using PET tracers by grouping them according to 
the underlying pathological processes that they reflect: inflammation, demyelination, neuronal 
damage and astrocyte activation (Table 2). 
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Inflammatory markers 
The acute, inflammatory activity in MS is characterised by breakdown of the blood–brain 
barrier, inflammatory cell infiltrates, microglial activation, and production of immune soluble 
mediators and harmful inflammatory enzymes. In the short-term, inflammation is responsible for 
the development of acute demyelinating lesions, with consequent clinical relapses.9,10 In the long-
term, demyelinated axons undergo neurodegeneration. Additionally, microglial cell activation is 
thought to have a short-term positive effect on tissue repair, but a long-term contribution to 
neuronal cell death.13,46,52 These inflammatory processes may be associated with increased PET 
signal detected in MS patients when compared to healthy controls. 
TSPO PET. The Translocator Protein (TSPO, formerly known as the peripheral 
benzodiazepine receptor or PBR) is an 18 kDa macromolecular complex, which is expressed at low 
levels in the outer mitochondrial membrane and is strongly up-regulated in activated microglial 
cells. Hence, TSPO ligands can reflect in-vivo the presence of activated microglial cells.13,46,52,53 
TSPO studies using 11C-PK11195 (a 3-isoquinolinecarboxamide antagonist with nanomolar 
affinity for TSPO) have reported increased uptake of this radiotracer in active MS lesions and in the 
NAWM than healthy controls,54,55 suggesting that this radiotracer might detect the widespread 
microglial cell activation in the active inflammatory rim of chronically active plaques and in the 
NAWM. Increased 11C-PK11195 uptake has been found also in the cortical GM of 10 RRMS and 8 
SPMS patients when compared to 8 healthy controls.54 Higher TSPO binding levels were associated 
with disability scores, particularly if located in clinically meaningful anatomic regions.55 
A few PET studies were carried out in small groups of MS patients using the second 
generation of TSPO tracers, such as 11C-vinpocetine, 11C-PBR28, 18F-FEDAA1106, 18F-PBR111 
and 18F-DPA714. An example of a PET scan showing the 11C-PBR28 uptake in MS is given in 
Figure 3. These novel radioligands are expected to overcome the relatively low brain uptake and 
non-specific binding of 11C-PK1119 with subsequent higher signal-to-noise ratios.10,46,51,53,56 
However, the TSPO polymorphisms, which explains differences in binding affinity of the PET 
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radioligand between subjects, needs to be considered when using the second generation TSPO 
ligands.13,57 Increased uptake of 18F-PBR111 was detected in WM lesions and NAWM of 11 MS 
patients, when compared with 11 healthy controls.56 Reduced uptake of 18F-PBR111 in the 
hippocampus of 13 RRMS patients, when compared to 22 healthy controls, was associated with 
higher scores at the Beck Depression Inventory, suggesting the involvement of this area in mood 
symptoms of MS.58 In an exploratory analysis comparing 4 RRMS patients with 4 healthy controls, 
11C-PBR28 presented a good test-retest reproducibility (less than 9%), and so might be suitable for 
future longitudinal assessments.59 
18F-FDG PET. Brain 2’-[18F] fluoro-2’-deoxyglucose (18F-FDG) PET measures the cerebral 
metabolic rate of glucose utilization and, hence, has been employed as a marker of inflammation. 
Higher metabolic rates are found in regions with ongoing inflammation due to an avid uptake from 
activated inflammatory cells.13,51 Specifically, 18F-FDG PET has been utilised in MS to classify 
WM lesions as either acute (hyper-metabolism) or chronic (hypo-metabolism) based on local 
glucose metabolism.60 
However, 18F-FDG uptake is not specific for inflammatory cells and is limited by the high 
background glucose uptake within the brain, which reduces its ability to detect small active 
lesions.13,51 It has been suggested that 18F-FDG uptake reflects glucose transport and metabolism by 
neurons and astrocytes, and, so, their integrity and functional state.10,60 In agreement with this 
hypothesis, a pilot 18F-FDG PET study of the spinal cord in 8 MS patients reported a lower uptake 
of this radioligand when compared to 8 healthy controls. Furthermore, a decreased 18F-FDG binding 
was associated with worse autonomic and walking symptoms,61 suggesting that an impaired 
metabolic activity in the spinal cord may be responsible for neurological disability. 
Purine PET. Adenosine is a ubiquitous purine that binds to a group of G-protein-coupled 
receptors (A1R, A2AR, A2BR, and A3R). A2A receptors are upregulated at sites of inflammation 
and tissue damage, thereby attenuating inflammation.51,62 11C-TMSX radioligand binds to adenosine 
A2A receptors. Rissanen and colleagues have carried out a PET study using this tracer in 10 SPMS 
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patients and 10 age- and sex-matched healthy controls.62 They found increased distribution volumes 
of 11C-TMSX in the NAWM of SPMS when compared with controls. Furthermore, the increased 
A2AR binding was associated with increased tissue loss and reduced fiber integrity, as measured by 
diffusion tensor imaging, and higher disability, as measured by the EDSS.62 
It is worth noting that this technique might be particularly valuable in measuring the impact of 
treatments modulating the adenosine pathways, such as caffeine-related compounds.51,63–65 
Purinergic pathways can be studied also by targeting the P2X7 receptor. Different tracers 
have been developed (e.g. 11C-JNJ-54173717, 11C-A-740003, 11C-GSK-1482160),57,66,67 and some 
of them have been tested on animal models of MS.57,66 These tracers might measure the activation 
of microglia and the associated release of inflammatory cytokines, and are expected to be tested 
soon in-vivo.68 
 
Myelin markers 
Demyelination is a hallmark of MS and can occur in both GM and WM. The inflammatory 
process causes the development of acute demyelinating lesions, which is associated with axonal 
transection.69 Demyelination can be followed by remyelination, or, in the long-term, 
neurodegeneration.9 
Amyloid PET. PET images with amyloid tracers, such as a carbon-labelled version of the 
Pittsburgh Compound B (11C-PIB) and 18F-Florbetaben, show normal uptake in healthy WM, 
thereby making the amyloid tracers potentially useful for studying MS.51,70,71 
In acute WM lesions, 11C-PIB and 18F-Florbetaben uptake was decreased when compared to 
NAWM, and a decreasing gradient in binding levels was found when going from the NAWM to the 
lesions,72,73 reflecting a more extensive myelin loss in acute lesions than in the NAWM. Both 
positive and negative variations in the binding of these PET ligands were observed in the chronic 
phase of the WM lesions, reflecting the net result of dynamic processes of myelin loss and 
remyelination. Additionally, in patients with RRMS, a higher 11C-PIB uptake within the WM 
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lesions was associated with a more benign clinical evolution.72 Progressive forms of MS showed a 
more pronounced reduction of the uptake in the damaged WM, in comparison to the RRMS type.73 
These studies suggest that in future amyloid-PET may be used to monitor MS progression and may 
be used to provide outcome measures in clinical trials designed to measure the effects of 
remyelinating agents.46,71 
11C-BMB (11C-1,4-bis(p-aminostyryl)-2-methoxybenzene) and its derivatives (i.e. 11C-CIC, 
along with 11C-MeDAS), which have showed promising results in animal models of MS, with 
concentration-dependent binding to WM tracts, will be investigated in humans.13,52 
 
Neuronal markers 
Neurodegenerative alterations occur even in the early stages of MS. Chronic modifications 
include activation of glial cells, infiltration of macrophages and, ultimately, neuronal functional 
alterations and death.1 In view of this, a variety of PET radioligands has been utilized to measure 
different components of these chronic neurodegenerative changes. 
11C-Flumazenil PET. 11C-Flumazenil is an antagonist of the central benzodiazepine receptor, 
a component of the ubiquitous GABA-A receptor complex present in the neuronal synapses in the 
GM. Thus, 11C-Flumazenil PET is a specific marker of neuronal integrity.2,13,74 
In a pilot study, Freeman and colleagues found a reduced 11C-Flumazenil cortical binding in 9 
RRMS and 9 SPMS patients, compared to 8 healthy controls. Interestingly, this difference was 
already seen in RRMS, who did not show a significant degree of GM atrophy. In addition, reduced 
GABA-A receptor binding was associated with impairment of information processing speed,74 
further suggesting the clinical relevance of this quantitative measure. These findings suggest that 
synaptic/dendritic damage may occur prior to a quantifiable grey matter volume loss, and contribute 
to clinical impairment. In future, neuroprotective and reparative treatment trials that aim to stop or 
slow down the progression of MS may consider developing the 11C-Flumazenil cortical binding as 
outcome measure for clinical trials or to select the patients who show early neurodegenerative 
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changes in the GM. 
 
Markers of astrocyte activation  
Glial (or astrocytic) cell activation and proliferation is known to occur since the early stage of 
MS, as discussed above in the myo-inositol section. Astrocytes are thought to play an important role 
in the pathogenesis of MS.75 
11C-Acetate PET. In MS lesions, activated glial cells overexpress metabolic enzymes, such as 
the monocarboxylate transporter,76 which absorbs acetate into astrocytes. The acetate is then 
converted into fatty acids. Takata and colleagues carried out an 11C-Acetate PET study in 6 RRMS 
patients and 6 healthy controls. An increased uptake of this radioligand was observed in both the 
WM and the GM of MS patients when compared to controls, but was more pronounced in the WM, 
particularly in the regions of axonal damage, as detected by diffusion-tensor imaging MRI.77 
Therefore, the detection of acetate has been suggested as a marker of astrocytic-associated damage 
in MS, although a development of a clinically feasible protocol for acetate PET and future 
investigations are warranted. 
Choline PET. A preliminary study by Virta and colleagues did not find any difference in the 
cortical uptake of the PET tracer 11C-MP4A, that reflects the acetylcholinesterase (AChE) activity, 
between 10 SPMS patients and 10 healthy controls.78 Nevertheless, 11C-Choline and 18F-Choline 
PET can evaluate the cholinergic metabolic profile of specific areas, such as large demyelinated 
lesions.79,80 
 
Limitations 
Possible limitations of PET imaging include: 1) the injection of radioactive tracers, although 
generally at low dosages; 2) PET costs which are still high for its application in the clinical practice; 
3) lack of standardized procedures (there is a need for data modelling techniques based on methods 
not dependent on reference plasma input or manual delineation of reference tissue region);54 4) 
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relatively low resolution of PET with subsequent difficulties in evaluating small plaques;77 5) static 
image acquisition in most protocols with subsequent difficulties in tracking the tracer over time. 
 
 
Conclusions 
Tags: Molecular and metabolic imaging; MR Spectroscopy; Positron Emission Tomography; 
Multiple Sclerosis; treatment; clinical trial; drug development; pathology; future. 
 
Despite the high costs of PET and the technical challenges of PET and MRS studies, these 
techniques have provided insights into the pathogenesis of MS and helped to understand the clinical 
heterogeneity of MS patients. The next step is to translate these techniques from the research 
laboratories to clinical trials and the clinical setting, in order to identify groups of patients who are 
more likely to respond to a medication and to monitor the treatment response. For example, 
reparative clinical trials testing the efficacy of remyelinating agents may in future benefit from 
inclusion of myelin PET into their trial design, perhaps to select patients who have the greatest 
remyelination potential.  
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Figure 1. Mechanisms of neurodegeneration and the molecular and metabolic imaging targets 
studied in MS. 
Inflammatory cells (e.g. lymphocytes, monocytes, microglia) produce reactive oxygen species and 
reactive nitrogen species, which contribute to mitochondrial injury. This leads to metabolic stress, 
energy deficiency and progressive loss of neuro-axonal function. Activation and proliferation of 
astrocytes occur to restore neuro-axonal function, although reactive astroglial cells also have 
harmful consequences on axonal survival. After acute demyelination, there is a redistribution of ion 
channels (e.g. Na+ channels), that, along with accumulation of Glutamate (the main excitatory 
neurotransmitter of the CNS), promotes ionic imbalance, with increased intracellular concentration 
of calcium and consequent neuronal apoptosis. The metabolites most commonly studied in MS are 
highlighted in the red boxes, and the targets of PET radioligands are shown in the blue boxes.  
MS: Multiple Sclerosis; CNS: Central Nervous System; MRS: Magnetic Resonance Spectroscopy; 
PET: Positron Emission Tomography. 
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Figure 2. Examples of the spectra on MRS in the corticospinal tract. 
Anatomy of the corticospinal tract (A), with the corresponding chemical shift imaging grid on a 
single image (B); spectrum from the voxel located above the left cerebral peduncle in a healthy 
control (C) (from Tur et al 2014, permission to reproduce requested).  
MRS: Magnetic Resonance Spectroscopy. 
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Figure 3. Example of TSPO PET scans in MS. 
T1 axial section from a 45 year old female patient with aggressive disease course (disease duration 
of 14 years) (A), and a 42 year old female patient with benign disease course with EDSS of 1.0 (B). 
The corresponding T1 overlaid with voxel-wise TSPO PET image of 11C-PBR28 distribution 
volume ratio (DVR) for patient A (C) and patient B (D). Bright yellow indicates high DVR and red 
is lower DVR. Overlaid on the images from (C) and (D) in (E) and (F), respectively, are the normal 
appearing white matter (in green) and T2 white matter lesion (in blue) masks (Courtesy of Dr 
Gourab Datta and Prof Paul Matthews, Imperial College London, UK).  
TSPO PET: Translocator Protein Positron Emission Tomography 
  
